EyePoint Blames Asymmetry For Phase III Trial Failure In Wet AMD
The first Phase III trial of Duravyu, EyePoint’s TKI injected in the eye every six months, failed on the primary endpoint of non-inferiority to the VEGF inhibitor Eylea but met all secondary endpoints.
Scrip - August 17, 2026

Enhertu Scores In NSCLC, Advancing AstraZeneca’s And Daiichi’s Growth Strategies
The HER2-targeting ADC beat out Merck’s Keytruda combined with chemotherapy in frontline HER2-mutant non-small cell lung cancer.
Scrip - August 17, 2026

Argenx’s Vyvgart Poised For First Rheumatology Expansion With Myositis Data
A successful Phase III study testing the FcRn inhibitor in immune-mediated necrotizing myopathy and dermatomyositis could represent two blockbuster-sized expansion opportunities.
Scrip - August 17, 2026

AstraZeneca’s Challenge To Keytruda Falters As Volrustomig Lung Trial Halted
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
Scrip - August 17, 2026

Silence Lays Out Phase III Plans For Divesiran In Polycythemia Vera
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
Scrip - August 17, 2026

Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 17, 2026

AZ’s First China Deal Finally Pays Off With Phase III NSCLC Win
AstraZeneca in-licensed savolitinib, a MET inhibitor, from HUTCHMED in 2011. Fifteen years later, the molecule delivers its first win in a global late-stage trial in certain types of non-small cell lung cancer.
Scrip - August 17, 2026

Executives On The Move: Six CEOs And Three CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Korsana Biosciences, Ascentage Pharma and Neurvati Neurosciences, plus BioNTech gets a new CEO.
Scrip - August 17, 2026

Japan Q1 Roundup: Forex Tailwind Lifts International Sales
Major Japanese pharma firms report generally strong fiscal Q1 results, buoyed by the weaker yen and robust specialist portfolio performance, particularly in ADCs and neurology.
Scrip - August 17, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.
Scrip - August 17, 2026

Samsung Galaxy Buds Join Apple AirPods In FDA-Cleared OTC Hearing Aid Category
Samsung has received FDA clearance for the hearing aid and hearing test features on two Galaxy Buds models, making it the second company after Apple to win authorization for a software-based OTC hearing aid in the US.
Medtech Insight - August 17, 2026

Mira Fertility Monitor’s Ad Claims Of Superiority Withdrawn On Clearblue Marketer P&G’s Challenge
National Advertising Division says Quanovate Tech withdrew numerous express claims for its Mira Fertility Monitor and Test Wands during review prompted by P&G challenge.
Medtech Insight - August 17, 2026

Medtronic Bets Its Surgical AI Future On Compute, Not Just The Hugo Robot
Medtronic has unveiled Touch Surgery Aide, an NVIDIA-based platform to run AI live during surgery, with a first FDA-cleared algorithm that flags when instruments leave a surgeon's view on its Hugo robot — a foundation its digital chief says will carry years of surgical AI.
Medtech Insight - August 17, 2026

Ambient AI Blurs Regulatory Line Between Record And Medical Device
New MHRA guidance hopes to clarify whether ambient scribing tools count as medical devices – but global ambiguity remains.
Medtech Insight - August 17, 2026

NVIDIA Wants To Become The Software Layer Supporting Surgical Robotics
The chipmaker is positioning itself not as a robot builder but as the foundational infrastructure for AI and robotics across medtech — from edge computing to open models and simulation. NVIDIA's David Niewolny tells Medtech Insight why the next race in surgical robotics will be won on software.
Medtech Insight - August 17, 2026

US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026

How To Approach GLP-1 Approvals: Anvisa Leads By Example
Five GLP-1 approvals from Anvisa are set to extend treatment options for poorly controlled type 2 diabetes mellitus patients.
Generics Bulletin - August 17, 2026

Fresenius Kabi Pulls US Tocilizumab Lot As Recall Count Mounts
Fresenius Kabi has recalled a US lot of Tyenne over glass particles, extending a run of nationwide quality-related recalls that has also affected morphine and famotidine products.
Generics Bulletin - August 17, 2026

Meloxicam Price Spike Leads UK Increases In July
Meloxicam tablets in multiple strengths led the UK’s steepest generic price rises in July, according to the latest figures from WaveData.
Generics Bulletin - August 17, 2026

Sandoz Adds Scale And Subcutaneous Option In Major Henlius Biosimilars Deal
Sandoz has struck a major expanded deal with Henlius covering up to 10 biosimilars, potentially lifting its pipeline to 46 assets as it prepares for a broader wave of biologic loss-of-exclusivity opportunities.
Generics Bulletin - August 17, 2026

Roche’s Barbara Lueckel On The Long Game In Research Technology Partnering
The global head of research technologies at Roche Pharma Partnering says novel modalities take time, trust matters as much as science, and compute power is the new currency of drug discovery.
In Vivo - August 17, 2026